PLOD2 and colorectal carcinoma: We began by analyzing the levels of PLOD2 in L1-expressing CRC cells in which the signaling by NF-κB was compromised by the expression of a shRNA against the p65 subunit of NF-κB (Figure 5A, L1 + shp65), or by expressing a mutant form of IκB that suppresses the NF-κB pathway (Figure 5A, L1 + IκB-SR).